NantKwest, Inc. was a pioneering, clinical-stage immunotherapy company dedicated to harnessing the innate power of the human immune system through natural killer (NK) cells. Their focus was on developing treatments for cancer, infectious diseases, and inflammatory conditions. NantKwest's proprietary 'off-the-shelf' activated NK (aNK) cell platform was engineered to identify and destroy cancerous and virally-infected cells. Founded by Dr. Patrick Soon-Shiong, the company aimed to be at the forefront of innovative cancer care. In March 2021, NantKwest completed a merger with ImmunityBio, Inc., combining their respective expertise and pipelines to advance a broad range of immunotherapeutic approaches.
Served as the central hub for NantKwest's corporate, administrative, and strategic operations. This included executive leadership, business development, financial management, and oversight of global research and development activities.
The Culver City headquarters likely consisted of modern office spaces designed for executive and administrative functions. More specialized facilities, such as advanced laboratories and cGMP manufacturing suites for their NK cell therapies, were primarily located at their San Diego site.
As a clinical-stage biotechnology firm, the work culture at NantKwest was likely characterized by intense research focus, innovation, and a fast-paced environment. Employees were driven by a strong mission to develop scientific breakthroughs for patients with critical unmet medical needs.
The headquarters was the nerve center for NantKwest's strategic direction and operational management in its pioneering work on NK cell therapies before its strategic combination with ImmunityBio.
Before merging with ImmunityBio, NantKwest's core operations, including R&D, manufacturing, and corporate functions, were predominantly based in the United States, particularly in California. Its international engagement was primarily through strategic collaborations and clinical trials conducted in various countries to evaluate the efficacy and safety of its novel NK cell therapies on a global scale.
9920 Jefferson Boulevard
Culver City
CA
USA
Address: 3530 John Hopkins Court, San Diego, CA 92121
Leveraged San Diego's prominent biotechnology cluster, providing access to a skilled talent pool, research collaborations, and specialized infrastructure vital for advancing NantKwest's innovative immunotherapy pipeline.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, NantKwest' leadership includes:
NantKwest has been backed by several prominent investors over the years, including:
In the year leading up to its merger with ImmunityBio (completed March 2021), NantKwest's executive team saw transitions mainly related to the upcoming combination. The primary standalone change was the departure of its CFO. Post-merger, a new leadership structure was formed for the combined entity, ImmunityBio.
Discover the tools NantKwest uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
NantKwest is now part of ImmunityBio, and its nantkwest.com email domain is no longer in active use for new communications. Historically, NantKwest likely utilized common corporate email patterns. For ImmunityBio, refer to their current email format.
Common historical patterns for NantKwest might have included [first_initial][last_name]@nantkwest.com (e.g., jdoe@nantkwest.com) or [first_name].[last_name]@nantkwest.com (e.g., jane.doe@nantkwest.com).
Format
jsmith@nantkwest.com
Example
0%
Success rate
GlobeNewswire • December 21, 2020
NantKwest and ImmunityBio announced a definitive agreement for an all-stock merger. The combination aimed to create a leading immunotherapy and cell therapy company by integrating NantKwest's natural killer cell platform with ImmunityBio's diverse immunotherapy pipeline, with Dr. Patrick Soon-Shiong to lead as Executive Chairman....more
Business Wire • November 8, 2019
NantKwest released its Q3 2019 financial results and provided updates on its clinical programs. Highlights included progress on its haNK cell therapy in combination treatments for various cancers and advancements in its off-the-shelf NK cell platform development, underscoring its commitment to advancing novel immunotherapies....more
PR Newswire • July 28, 2015
NantKwest announced the pricing of its initial public offering (IPO) of 8,295,000 shares of common stock at a price of $25.00 per share. The shares began trading on the Nasdaq Global Select Market under the ticker symbol 'NK'. This IPO marked a significant milestone for the company in funding its innovative NK cell therapy research....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including NantKwest, are just a search away.